Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study

Author(s): Smith NL, Wiley JR, Legault C, Rice KM, Heckbert SR, et al.

Abstract

Background: Accelerated bone loss after stopping hormone therapy (HRT) is postulated to explain the lack of hip-fracture protection conferred by former HRT use. The abbreviation HRT (traditionally standing for "hormone replacement therapy") is used herein because of its wide recognition in the field. However, the pharmacological doses of estrogens and progestins used are not truly "replacement" in nature.

Objectives: To determine whether women lose bone mineral density (BMD) after stopping HRT; to assess whether their rate of loss is significantly greater than that of women not undergoing HRT; and to determine whether long-term HRT is associated with continued gains in BMD.

Methods: A total of 495 women who were adherent to assigned treatment in the 3-year Postmenopausal Estrogen/Progestin Interventions randomized controlled trial (PEPI-RCT) and who had an additional BMD measurement during the PEPI Safety Follow-up Study were observed for an average of 3 years during and 4 years after the PEPI-RCT.

Results: Women who stopped HRT after 1 year during the PEPI-RCT had annual rates of BMD change of -0.54% (hip) and -0.81% (spine) during the following 2 years. Those who underwent HRT for 3 years during the PEPI-RCT and then discontinued it had annual changes of -1.01% (hip) and -1.04% (spine). Rates of BMD loss among women who stopped HRT during or after the PEPI-RCT did not differ significantly from those of women who did not undergo HRT, who lost bone at a rate of approximately 1% yearly during the first year of the PEPI-RCT and about half that rate afterward. Women who continued HRT after the PEPI-RCT did not show additional BMD gains.

Conclusions: Our results do not support the hypothesis that bone is lost at an unusually fast rate after discontinuation of HRT, nor do they suggest that longer-term HRT leads to additional BMD gain beyond that evident after 3 years.

Similar Articles

LDL cholesterol: the lower the better

Author(s): Martin SS, Blumenthal RS, Miller M

High density lipoproteins and atherosclerosis: emerging aspects

Author(s): Sala F, Catapano AL, Norata GD

High-density lipoprotein function, dysfunction, and reverse cholesterol transport

Author(s): Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD

Targeting Innate Immunity for CV Benefit

Author(s): Moore KJ, Freeman MW

Blood serum atherogenicity associated with coronary atherosclerosis

Author(s): Orekhov AN, Tertov VV, Pokrovsky SN, Adamova IYu, Martsenyuk ON, et al.

Characteristics of low density lipoprotein isolated from circulating immune complexes

Author(s): Tertov VV, Sobenin IA, Orekhov AN, Jaakkola O, Solakivi T, et al.

Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein

Author(s): Tertov VV, Kaplun VV, Sobenin IA, Boytsova EY, Bovin NV, et al.

Presence of a modified low density lipoprotein in humans

Author(s): Avogaro P, Bon GB, Cazzolato G

Autoantibodies against modified low density lipoprotein

Author(s): Orekhov AN, Tertov VV, Kabakov AE, Adamova IYu, Pokrovsky SN, et al.

Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis

Author(s): Tertov VV, Orekhov AN, Kacharava AG, Sobenin IA, Perova NV, et al.

Lipoprotein immune complexes as markers of atherosclerosis

Author(s): Orekhov AN, Kalenich OS, Tertov VV, Novikov ID

Diagnostic value of immune cholesterol as a marker for atherosclerosis

Author(s): Orekhov AN, Kalenich OS, Tertov VV, Perova NV, Novikov IyD, et al.

Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis

Author(s): Sobenin IA, Karagodin VP, Melnichenko AC, Bobryshev YV, Orekhov AN

Pluronic block copolymers inhibit low density lipoprotein self-association

Author(s): Melnichenko AA, Aksenov DV, Myasoedova VA, Panasenko OM, Yaroslavov AA, et al.

Three-dimensional cytoarchitecture of normal and atherosclerotic intima of human aorta

Author(s): Rekhter MD, Andreeva ER, Mironov AA, Orekhov AN

Primary cultures of enzyme-isolated cells from normal and atherosclerotic human aorta

Author(s): Orekhov AN, Andreeva ER, Krushinsky AV, Smirnov VN

Lipids in cells of atherosclerotic and uninvolved human aorta

Author(s): Orekhov AN, Tertov VV, Novikov ID, Krushinsky AV, Andreeva ER, et al.

Adult human aortic cells in primary culture: heterogeneity in shape

Author(s): Orekhov AN, Krushinsky AV, Andreeva ER, Repin VS, Smirnov VN

Cell proliferation in normal and atherosclerotic human aorta

Author(s): Orekhov AN, Kosykh VA, Repin VS, Smirnov VN

Primary culture of human aortic intima cells as a model for testing anti-atherosclerotic drugs

Author(s): Orekhov AN, Tertov VV, Kudryashov SA, Khashimov KhA, Smirnov VN

Atherogenicity of blood serum from patients with coronary heart disease

Author(s): Chazov EI, Tertov VV, Orekhov AN, Lyakishev AA, Perova NV, et al.

Antiatherosclerotic effects of calcium antagonists

Author(s): Orekhov AN, Baldenkov GN, Tertov VV, Ruda MYa, Khashimov KA, et al.

Effects of garlic on atherosclerosis

Author(s): Orekhov AN, Grünwald J

Anti-atherosclerotic therapy based on botanicals

Author(s): Orekhov AN, Sobenin IA, Korneev NV, Kirichenko TV, Myasoedova VA, et al.

The antiatherosclerotic effect of Allium sativum

Author(s): Koscielny J, Klüssendorf D, Latza R, Schmitt R, Radtke H, et al.

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) Am J Cardiol 75: 455-459

Author(s): Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, et al.

Kuopio Atherosclerosis Prevention Study (KAPS)

Author(s): Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, et al.

Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events

Author(s): Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, et al.

Beneficial effects of colestipol-niacin therapy on the common carotid artery

Author(s): Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu CR, et al.

Coronary angiographic changes with lovastatin therapy

Author(s): Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, et al.

Carotid plaque morphologic characteristics

Author(s): Aidinian G, Weiswasser JM, Arora S, Abularrage CJ, Singh N, et al.

Thematic review series: The immune system and atherogenesis

Author(s): Daugherty A, Webb NR, Rateri DL, King VL

Evidence-based assessment of the impact of the WHI on women's health

Author(s): Burger HG, MacLennan AH, Huang KE, Castelo-Branco C